Literature DB >> 7931434

HLA and prognosis in multiple sclerosis.

B Runmarker1, T Martinsson, J Wahlström, O Andersen.   

Abstract

The patients of a multiple sclerosis (MS) incidence cohort with 25 years of longitudinal follow-up were typed for HLA-DR and DQ. This type of cohort provides reliable data for gene frequencies and prognostic studies. The influence of sampling bias, mainly due to mortality during the long follow-up, was accounted for. A positive association between MS and DR15,DQ6 was confirmed, but this haplotype did not influence prognosis. There was no difference in haplotype frequency between relapsing-remitting and primary chronic progressive MS. DR17,DQ2 was significantly over-represented in the quartile with the most malignant course. The haplotype DR1,DQ5, which was found rather less frequently in MS patients, also tended to be associated with a poorer prognosis.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7931434     DOI： 10.1007/bf02033356

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  37 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Immunogenetic profile of multiple sclerosis in Mexicans.

Authors:  C Gorodezky; R Najera; B E Rangel; L E Castro; J Flores; G Velázquez; J Granados; J Sotelo
Journal:  Hum Immunol       Date:  1986-08       Impact factor: 2.850

Review 3.  HLA class II genes: typing by DNA analysis.

Authors:  J L Bidwell; E A Bidwell; B A Bradley
Journal:  Baillieres Clin Haematol       Date:  1990-04

4.  Multiple sclerosis: nature or nurture?

Authors:  D C Skegg
Journal:  BMJ       Date:  1991-02-02

5.  HLA-DR beta, -DQ alpha, and -DQ beta restriction fragment length polymorphisms in multiple sclerosis.

Authors:  D G Haegert; M Michaud; C Schwab; C Tansey; F Décary; G Francis
Journal:  J Neurosci Res       Date:  1989-05       Impact factor: 4.164

6.  Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.

Authors:  P Duquette; F Décary; J Pleines; D Boivin; G Lamoureux; J B Cosgrove; Y Lapierre
Journal:  Can J Neurol Sci       Date:  1985-05       Impact factor: 2.104

7.  Histocompatibility determinants in multiple sclerosis, with special reference to clinical course.

Authors:  C Jersild; T Fog; G S Hansen; M Thomsen; A Svejgaard; B Dupont
Journal:  Lancet       Date:  1973-12-01       Impact factor: 79.321

8.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

9.  Different B lymphocyte alloantigens associated with multiple sclerosis in Arabs and North Europeans.

Authors:  A Kurdi; I Ayesh; A Abdallat; U Maayta
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

10.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422
View more
  6 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

4.  Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis.

Authors:  K M Drescher; L T Nguyen; V Taneja; M J Coenen; J L Leibowitz; G Strauss; G J Hammerling; C S David; M Rodriguez
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

6.  Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.

Authors:  Cathy J Jensen; Jim Stankovich; Anneke Van der Walt; Melanie Bahlo; Bruce V Taylor; Ingrid A F van der Mei; Simon J Foote; Trevor J Kilpatrick; Laura J Johnson; Ella Wilkins; Judith Field; Patrick Danoy; Matthew A Brown; Justin P Rubio; Helmut Butzkueven
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.